# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Leerink Partners analyst Andrew Berens downgrades Viracta Therapeutics (NASDAQ:VIRX) from Outperform to Market Perform and l...
RBC Capital analyst Gregory Renza maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target...
Viracta Therapeutics stock gains after Phase 2 NAVAL-1 trial results for relapsed or refractory EBV+ PTCL cohort. The company p...
Additionally, the Company received productive feedback from its meeting with the U.S. Food and Drug Administration (FDA), prov...
https://patentcenter.uspto.gov/applications/18240853/ifw/docs